# Catalyst Pharmaceuticals share price (Catalyst Pharmaceuticals, Inc., CPRX)

> Catalyst Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CPRX · Healthcare · Biotechnology · data as of 14 July 2026. Page: https://www.sectoralpha.in/us/stocks/cprx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from the last 12 quarters
- Price: $31.49 (+44.4% in a year)
- P/E: 18.2× (higher than 54% of the last 4.3 years)
- Revenue (Mar 2026): $149 M (+5.6% on a year ago)
- Profit (Mar 2026): $63.7 M (+12.3% on a year ago)
- Operating margin: 49.0% (+4.2 points on a year ago)
- ROE: 23%, FY25
- ROIC: 78.8%, against a 8.3% cost of capital: +70.5 points

Biggest thing to watch: the price has already been rising for 13 weeks, so timing is the risk more than the business. ## What is the Catalyst Pharmaceuticals share price? Catalyst Pharmaceuticals, Inc.'s share price was $31.49 at the close on 14 July 2026. It has been rising for 13 weeks. That is 24.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between $20 and $32, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 20 weeks in a row. Over the last 10 years the share price moved +3,836% while the S&P 500 moved +250%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Catalyst Pharmaceuticals pay? Catalyst Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Catalyst Pharmaceuticals on? Catalyst Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Catalyst Pharmaceuticals profitable? Catalyst Pharmaceuticals, Inc. earned $63.7 M of net profit in the Mar 2026 quarter, +12.3% on the same quarter a year earlier. Full-year FY25 profit was $214 M. Over 4 years profit has grown 52.6% a year on average. That is 42.7% of the quarter's revenue. The same quarter a year earlier earned $56.7 M. 1 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $214 M (+30.8% on the year before). Why profit moved: revenue changed +5.6% on a year earlier and the margin moved +4.2 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +13.6% and revenue +12.0%. Profit and revenue are moving at about the same pace. ## How much revenue does Catalyst Pharmaceuticals make, and is it growing? Catalyst Pharmaceuticals, Inc. reported $149 M of revenue in the Mar 2026 quarter, +5.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 43.0% a year on average. The last full year, FY25, came in at $589 M. The last four reported quarters add to $597 M. FY25 revenue was $589 M, +19.8% on the year before. Recent pace: the last four quarters grew +12.0% on average, against 43.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.7%, against +20.5% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +12.1%, against +84.4% a year (rolling over). ## How much of every $100 of sales does Catalyst Pharmaceuticals keep? Catalyst Pharmaceuticals, Inc.'s operating margin was 49.0% in the Mar 2026 quarter, 4.2 percentage points higher than the same quarter a year ago. Across 5 years it has been between 21.8% and 47.5%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +4.2 percentage points on the year while gross margin changed +3.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Catalyst Pharmaceuticals' profit turning into cash? Over the last 3 years, 132% of Catalyst Pharmaceuticals, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $209 M of operating cash against $214 M of profit. After $58.0 K of spending on assets, $209 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Catalyst Pharmaceuticals' cash go? Catalyst Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $199 M on assets over the last 3 years. Averaged over those years that is 11.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $199 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Catalyst Pharmaceuticals' P/E ratio, and how does it compare with its own history? Catalyst Pharmaceuticals, Inc.'s P/E is 18.2×, in the middle of its own history: higher than 54% of past readings. Its usual P/E (the middle reading) is 18.0×, over 4.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +28.2% while the price moved +44.4%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +34.8% a year; about +19.5% a year came from earnings growth and about +15.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Catalyst Pharmaceuticals business getting better or worse? Catalyst Pharmaceuticals, Inc.'s business is slowing from a peak. Revenue, profit and EPS growth have slowed sharply (revenue growth from +81.7% at its peak to +11.7% now), while ROCE is still 29.5%. This is based on 12 quarters of 4 measures. Why it matters: slowing from a peak is where good stories often end quietly. ## How much does Catalyst Pharmaceuticals earn on its capital? Catalyst Pharmaceuticals, Inc. earned a ROE of 23% in FY25. That is up from a low of 18% in FY23. Its return on capital used (ROIC) is 70.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 36.4% net margin and 0.53× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 36.4% net margin × 0.53× asset turnover × 1.16× leverage (assets divided by equity) ≈ 22.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 78.8% − 8.3% = +70.5 percentage points. The 8.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 78.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 84.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Catalyst Pharmaceuticals have too much debt? Catalyst Pharmaceuticals, Inc. has total debt of $2.7 M against shareholder equity of $1.0 B as of Mar 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.02 in FY21 to 0.00 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Catalyst Pharmaceuticals shareholding pattern? 6.8% of Catalyst Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Catalyst Pharmaceuticals from balance-sheet trouble? For Catalyst Pharmaceuticals, Inc., the Z-score is 15.04. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 15.04 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Catalyst Pharmaceuticals rank in its industry? There is no score against its industry: Catalyst Pharmaceuticals, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Catalyst Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Catalyst Pharmaceuticals in size? Catalyst Pharmaceuticals is the 48th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Travere Therapeutics, Inc., Dianthus Therapeutics, Inc. and Legend Biotech Corporation. Just below it: Relay Therapeutics, Inc., ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. ### Biotechnology companies close in size

1. [Travere Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/tvtx) $4.7 billion
2. [Dianthus Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/dnth) $4.6 billion
3. [Legend Biotech Corporation](https://www.sectoralpha.in/us/stocks/legn) $4.4 billion
4. Catalyst Pharmaceuticals, Inc. $3.9 billion
5. [Relay Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/rlay) $3.7 billion
6. [ACADIA Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/acad) $3.7 billion
7. [Xenon Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/xene) $3.6 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [BancFirst Corporation](https://www.sectoralpha.in/us/stocks/banf) $3.9 billion · Banks - Regional
2. [First Advantage Corporation](https://www.sectoralpha.in/us/stocks/fa) $3.9 billion · Specialty Business Services
3. Catalyst Pharmaceuticals, Inc. $3.9 billion
4. [Polaris Inc.](https://www.sectoralpha.in/us/stocks/pii) $3.9 billion · Recreational Vehicles
5. [Calumet, Inc.](https://www.sectoralpha.in/us/stocks/clmt) $3.8 billion · Specialty Chemicals

## What else do people ask about Catalyst Pharmaceuticals? ### What were Catalyst Pharmaceuticals's latest quarterly results? Catalyst Pharmaceuticals, Inc. reported revenue of $149 M and net profit of $63.7 M for the Mar 2026 quarter. Revenue rose 5.6% and profit rose 12.3% compared with a year earlier. Earnings per share were $0.50. The operating margin was 49.0%, 4.2 percentage points higher than a year earlier (as of 14 July 2026). ### What is Catalyst Pharmaceuticals's market cap? Catalyst Pharmaceuticals, Inc.'s market capitalisation is $3.9 B at a stock price of $31.49. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 14 July 2026). ### How is Catalyst Pharmaceuticals performing? Catalyst Pharmaceuticals, Inc.'s share price has been rising for 13 weeks. In its latest quarter, revenue rose 5.6% and profit rose 12.3% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 20 weeks running (as of 14 July 2026). ### Will Catalyst Pharmaceuticals's stock price go up? This page does not forecast Catalyst Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $31.49, and it has been rising for 13 weeks. Its P/E of 18.2× is higher than 54% of its own last 4 years (as of 14 July 2026). ### Is Catalyst Pharmaceuticals's profit real cash? Yes, over the last 3 years, 132% of Catalyst Pharmaceuticals, Inc.'s reported profit came in as cash from operations. The latest year was lower at 97%, so the trend is worth watching. In FY25, operating cash was $209 M against reported profit of $214 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 14 July 2026). ### Where is Catalyst Pharmaceuticals in its business cycle? Catalyst Pharmaceuticals, Inc.'s FY25 operating margin was 43.8%, against a 5-year range of 21.8% to 47.5%: the middle of its own range, neither a peak nor a low. The latest quarter was 49.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 14 July 2026). ### What could break the Catalyst Pharmaceuticals story? Biggest thing to watch: the price has already been rising for 13 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 14 July 2026). ### Is Catalyst Pharmaceuticals a stock worth studying right now? What the numbers show: Catalyst Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 14 July 2026). This is research, not advice. We’re not SEBI-registered.